Table 1.
Baseline clinical characteristics of Alzheimer’s disease dementia patients in this study
| Parameters | 2019.1–2019.10 (N=72) | 2019.11–2021.3 (N=58) | Value (N=130) | p-value |
|---|---|---|---|---|
| Age (yr) | 0.56 | |||
| Mean±SD | 79.89±5.98 | 79.31±5.14 | 79.63±5.60 | |
| Median (range) | 80 (60–93) | 79 (69–91) | 80 (60–93) | |
| Sex, male | 25 (34.72) | 20 (34.48) | 45 (34.62) | 0.98 |
| Body mass index (kg/m2) | 0.11 | |||
| Mean±SD | 23.75±3.27 | 22.83±2.95 | 23.34±3.15 | |
| Median (range) | 23.59 (16.80–32.89) | 22.65 (17.78–29.21) | 23.05 (16.80–32.89) | |
| Family history of dementia (yes) | 15 (20.83) | 10 (17.24) | 25 (19.23) | 0.61 |
| Underlying diseases | ||||
| Diabetes mellitus | 14 (19.44) | 14 (24.14) | 28 (21.54) | 0.52 |
| Hypertension | 39 (54.17) | 34 (58.62) | 73 (56.15) | 0.61 |
| Hyperlipidemia | 15 (20.83) | 19 (32.76) | 34 (26.15) | 0.12 |
| Years of education | 0.93 | |||
| Mean±SD | 10.83±5.02 | 11.19±4.49 | 10.99±4.77 | |
| Median (range) | 12 (0–18) | 12 (0–19) | 12 (0–19) | |
| Apolipoprotein E genotype | 0.76 | |||
| E2/E2 | 2 (2.78) | 0 | 2 (1.54) | |
| E2/E3 | 3 (4.17) | 3 (5.17) | 6 (4.62) | |
| E3/E3 | 32 (44.44) | 27 (46.55) | 59 (45.38) | |
| E2/E4 | 2 (2.78) | 2 (3.45) | 4 (3.08) | |
| E3/E4 | 19 (26.39) | 16 (27.59) | 35 (26.92) | |
| E4/E4 | 2 (2.78) | 4 (6.90) | 6 (4.62) | |
| Unknown | 12 (16.67) | 6 (10.34) | 18 (13.85) | |
| Kind of acetylcholine esterase inhibitor | 0.01 | |||
| Donepzil | 28 (38.89) | 34 (58.62) | 62 (47.69) | |
| Rivastigmine | 4 (5.56) | 6 (10.34) | 10 (7.69) | |
| Galantamine | 39 (54.17) | 16 (27.59) | 55 (42.31) | |
| Unknown | 1 (1.39) | 2 (3.45) | 3 (2.31) |
Values are presented as number (%) unless otherwise indicated. SD, standard deviation